Cardinal Health Projects 13 to 15 Percent EPS Growth on Specialty Drug Gains

Cardinal Health's guidance signals that specialty pharmaceutical distribution is becoming the primary earnings driver for one of the largest US healthcare supply companies, a shift that could...

Cardinal Health, the Dublin, Ohio-based healthcare distribution company, has set a target of 13 to 15 percent annual earnings-per-share growth, citing accelerating momentum in its specialty pharmaceutical segment, according to a company presentation reported by Yahoo Finance on September 19, 2026.

The EPS growth target is the central figure the company is now presenting to investors as its forward operating case. At Cardinal Health's most recently reported trailing twelve-month EPS, a 13 to 15 percent compounding rate would represent a material upward revision from the growth rates the company posted in its pharmaceutical distribution core business over the prior three fiscal years, based on figures in Cardinal Health's most recent annual report filed with the Securities and Exchange Commission.

Specialty pharmaceuticals, which include biologics, oncology drugs, and other complex therapies, carry higher margins than the company's traditional generics and branded drug distribution business. Cardinal Health has been expanding its Specialty segment, which serves physician offices, hospitals, and health systems that administer drugs in clinical settings rather than through retail pharmacy channels.

Cardinal Health is one of three companies, alongside McKesson and AmerisourceBergen (now Cencora), that collectively distribute a large majority of prescription pharmaceuticals in the United States. The structure of the US drug supply chain places these distributors between manufacturers and dispensing points, meaning their revenue volume is closely tied to overall US drug spending.

The US specialty pharmaceutical market has grown at a rate that outpaces the broader prescription drug market. The Centers for Medicare and Medicaid Services reported in its National Health Expenditure data that spending on retail prescription drugs and clinical administered drugs has risen each year since 2020, with specialty and biologic therapies accounting for a growing share of that total.

Cardinal Health's Specialty segment reported revenue growth in its most recent quarterly earnings filing with the SEC. The company has not disclosed a precise percentage breakdown of how much of the projected EPS growth comes from specialty versus its legacy pharmaceutical distribution or its medical products segment. That breakdown would be a key figure for investors assessing execution risk on the guidance.

The 13 to 15 percent EPS growth target is forward guidance, which is not audited and carries inherent uncertainty. The specific assumptions underlying the projection, including volume growth rates, pricing, and margin expansion expectations, were not fully detailed in the reported summary. Cardinal Health's next full investor day presentation or quarterly earnings call would be the events most likely to disclose the model inputs.

Cardinal Health stock trades on the New York Stock Exchange under the ticker CAH. The company's market capitalization, based on share price and shares outstanding as reported in its most recent SEC filing, places it among the larger companies in the S&P 500 healthcare sector. Changes in EPS guidance at this scale have historically moved the stock, though the magnitude depends on how the new target compares to existing analyst consensus estimates published by services such as Bloomberg or FactSet.

The medical segment remains a secondary but notable part of Cardinal Health's business. The company has been restructuring that unit after absorbing losses tied to product sourcing and supply chain costs in prior fiscal years, as disclosed in its SEC filings. Whether the specialty momentum offsets any continued pressure in medical products is a question the guidance does not fully resolve.

For US investors, Cardinal Health's guidance is also a signal about the broader trajectory of specialty drug administration in clinical settings, a market shaped by FDA approval rates for biologics, insurer reimbursement policy, and the expansion of Medicare coverage under the Inflation Reduction Act's drug pricing provisions. Any changes to Medicare Part B reimbursement rates, which govern many physician-administered specialty drugs, would directly affect Cardinal Health's specialty revenue base.